drugset / Trial / NCT03555539
Study of Danicopan in Participants With Hepatic Impairment
Phase 1
Completed
16 enrolled
Alexion Pharmaceuticals, Inc.
Achillion, a wholly owned subsidiary of Alexion · collab
Non-randomizedParallel-groupOpen-labelBasic science
Summary
The purpose of this study was to evaluate the safety, tolerability, and pharmacokinetics (PK) of ACH-0144471 (danicopan) in participants with hepatic impairment (HI) as compared to healthy matched participants.
Timeline
- Start
- 2018-05-01
- Primary completion
- 2018-09-21
- Completion
- 2018-09-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Danicopan | Small molecule | 200 mg | Oral |
Indications
No indication recorded.